Physician

Brett E Stanaland, MD

According to 2025 Medicare claims, Brett Stanaland, MD (NPI: 1508865924) practices allergy/immunology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is BRETT E. STANALAND, M.D., P.A. (NPI: 1710174602; TIN: 593283209) and primary practice location at 34102-5474.

Stanaland's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,436 traditional Medicare patients, billed 89,101 HCPCS/CPT codes, and received $1,693,506 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 4,786 prescription claims across 1,068 beneficiaries totaling $1,441,630 in drug costs, led by Haegarda (C1 Esterase Inhibitor). DME data shows 768 claims. Open Payments data shows 201 records totaling $195,588. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $238,686 to $1,693,506. Similarly, Part D prescription costs have moved sharply higher in recent years, from $713,259 to $1,441,630. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $17,442 and ending at $10,587.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	995	19,540	$238,686
2016	1,191	24,009	$285,114
2017	1,141	20,152	$242,732
2018	1,148	23,591	$262,061
2019	1,107	27,796	$474,618
2020	1,038	39,445	$842,767
2021	1,047	43,194	$985,100
2022	1,334	56,054	$1,267,258
2023	1,460	78,098	$1,513,708
2024	1,436	89,101	$1,693,506

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	782	3,972	$713,259
2016	962	4,802	$780,057
2017	965	4,918	$874,639
2018	986	4,617	$872,542
2019	1,001	4,911	$939,591
2020	998	5,323	$1,123,127
2021	994	5,070	$1,092,856
2022	989	5,153	$1,664,825
2023	1,009	5,110	$1,661,073
2024	1,068	4,786	$1,441,630

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	37	631	$785,239
2016	37	726	$884,503
2017	68	713	$1,004,857
2018	58	835	$943,040
2019	75	1,027	$1,150,687
2020	113	1,108	$1,415,173
2021	63	895	$1,480,853
2022	48	703	$1,318,777
2023	32	764	$1,423,544
2024	49	768	$1,386,719

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	296	296	$116
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	1,296	2,047	$65
95165	Professional service for preparation and provision of 1 or more antigens	239	6,350	$11
95117	Professional service for multiple injections of allergen	266	3,032	$9
95004	Test for allergy using allergenic extract	196	11,797	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Haegarda	C1 Esterase Inhibitor	17	476	$537,025
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	405	16,290	$334,300
Breo Ellipta	Fluticasone/Vilanterol	134	6,840	$87,797
Rinvoq	Upadacitinib	12	420	$83,611
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	67	2,490	$50,624

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	124	$630,009
J1559	Injection, immune globulin (hizentra), 100 mg	N	11	125	$404,280
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	59	$180,059
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	13	$87,629
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	13	$70,251

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	201	$195,588	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Brett E. Stanaland, MD?

Tedicare shows public-source Medicare data for Brett E. Stanaland, MD (NPI 1508865924), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brett E. Stanaland, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Brett E. Stanaland, MD?

Brett E. Stanaland, MD is linked to BRETT E. STANALAND, M.D., P.A. (billing NPI 1710174602) in the available physician profile data.

Does Brett E. Stanaland, MD have Open Payments data?

Brett E. Stanaland, MD has 201 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.